Aprea Therapeutics (APRE) Stock Price, News & Analysis

Company Overview

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

Key Stats

• Today's Range: $1.55 to $1.81
• 50-Day Range: $1.47 to $2.84
• 52-Week Range: $1.41 to $5.90
• Volume: 83,736 shs
• Average Volume: 20,719 shs
• Market Capitalization: $9.61 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $15.50
• Consensus Rating: Buy

Aprea Therapeutics Stock Analysis - MarketRank™

Aprea Therapeutics scored higher than 63% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Aprea Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Aprea Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Aprea Therapeutics are expected to grow in the coming year, from ($2.55) to ($0.95) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Aprea Therapeutics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Aprea Therapeutics is -0.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Aprea Therapeutics has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.25% of the float of Aprea Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aprea Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aprea Therapeutics has recently increased by 1.17%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Aprea Therapeutics does not currently pay a dividend.

Dividend Growth

Aprea Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.25% of the float of Aprea Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Aprea Therapeutics has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Aprea Therapeutics has recently increased by 1.17%, indicating that investor sentiment is decreasing.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: 0.93

News Sentiment

Aprea Therapeutics has a news sentiment score of 0.93. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Aprea Therapeutics this week, compared to 1 article on an average week.

MarketBeat Follows

2 people have added Aprea Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 2.5 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Aprea Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $10,120.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

12.80% of the stock of Aprea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 34.19% of the stock of Aprea Therapeutics is held by institutions.

APRE Stock Analysis - Frequently Asked Questions

How have APRE shares performed this year?

Aprea Therapeutics' stock was trading at $3.29 on January 1st, 2025. Since then, APRE shares have decreased by 46.8% and is now trading at $1.75.
View the best growth stocks for 2025 here.

How were Aprea Therapeutics' earnings last quarter?

Aprea Therapeutics, Inc. (NASDAQ:APRE) released its quarterly earnings results on Tuesday, March, 25th. The company reported ($0.49) earnings per share for the quarter, topping analysts' consensus estimates of ($0.69) by $0.20. The business had revenue of $0.21 million for the quarter, compared to the consensus estimate of $0.15 million. Aprea Therapeutics had a negative trailing twelve-month return on equity of 57.86% and a negative net margin of 1,029.50%.

When did Aprea Therapeutics' stock split?

Aprea Therapeutics shares reverse split on Monday, February 13th 2023. The 1-20 reverse split was announced on Monday, February 13th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, February 13th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

When did Aprea Therapeutics IPO?

Aprea Therapeutics (APRE) raised $52 million in an initial public offering on Thursday, October 3rd 2019. The company issued 5,000,000 shares at $19.00-$2.00 per share. J.P. Morgan, Morgan Stanley and RBC Capital Markets served as the underwriters for the IPO.

How do I buy shares of Aprea Therapeutics?

Shares of APRE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Aprea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Aprea Therapeutics investors own include Tesla (TSLA), HubSpot (HUBS), Netflix (NFLX), Adverum Biotechnologies (ADVM), Biogen (BIIB), Sarepta Therapeutics (SRPT) and Corbus Pharmaceuticals (CRBP).

Company Calendar

• Last Earnings: 3/25/2025
• Today: 4/29/2025
• Next Earnings (Estimated): 5/13/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:APRE
• CIK: 1781983
• Web: www.aprea.com
• Phone: 617-463-9385
• Fax: N/A
• Employees: 7
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $15.50
• High Stock Price Target: $20.00
• Low Stock Price Target: $11.00
• Potential Upside/Downside: +785.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($2.38)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-14,290,000.00
• Net Margins: -1,029.50%
• Pretax Margin: -1,029.50%
• Return on Equity: -57.86%
• Return on Assets: -47.94%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 7.28
• Quick Ratio: 7.28

Sales & Book Value

• Annual Sales: $580,000.00
• Price / Sales: 16.57
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.54 per share
• Price / Book: 0.39

Miscellaneous

• Outstanding Shares: 5,492,000
• Free Float: 4,739,000
• Market Cap: $9.61 million
• Optionable: No Data
• Beta: 1.04